Altimmune Inc (NASDAQ: ALT) kicked off on Tuesday, down -3.57% from the previous trading day, before settling in for the closing price of $5.45. Over the past 52 weeks, ALT has traded in a range of $5.22-$11.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 104.92% over the past five years. While this was happening, its average annual earnings per share was recorded -9.53%. With a float of $76.22 million, this company’s outstanding shares have now reached $77.01 million.
Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is -740.0%, operating margin of -515860.0%, and the pretax margin is -475295.0%.
Altimmune Inc (ALT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Altimmune Inc is 1.03%, while institutional ownership is 53.06%. The most recent insider transaction that took place on Aug 19 ’24, was worth 110,547. In this transaction Director of this company sold 16,011 shares at a rate of $6.90, taking the stock ownership to the 41,958 shares.
Altimmune Inc (ALT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.98% during the next five years compared to 3.48% growth over the previous five years of trading.
Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators
Take a look at Altimmune Inc’s (ALT) current performance indicators. Last quarter, stock had a quick ratio of 13.10. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20254.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.69 in one year’s time.
Technical Analysis of Altimmune Inc (ALT)
Altimmune Inc (NASDAQ: ALT) saw its 5-day average volume 2.89 million, a positive change from its year-to-date volume of 2.33 million. As of the previous 9 days, the stock’s Stochastic %D was 11.18%. Additionally, its Average True Range was 0.41.
During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 1.83%, which indicates a significant decrease from 6.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.01% in the past 14 days, which was lower than the 79.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.62, while its 200-day Moving Average is $7.00. Nevertheless, the first resistance level for the watch stands at $5.42 in the near term. At $5.59, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.72. If the price goes on to break the first support level at $5.12, it is likely to go to the next support level at $4.99. Assuming the price breaks the second support level, the third support level stands at $4.82.
Altimmune Inc (NASDAQ: ALT) Key Stats
The company with the Market Capitalisation of 405.09 million has total of 77,014K Shares Outstanding. Its annual sales at the moment are 20 K in contrast with the sum of -95,060 K annual income. Company’s last quarter sales were recorded 10 K and last quarter income was -23,180 K.
